BRPI0407904A - processo para a preparação de sal de 5-[(r)-2-(5,6-dietil-indan-2-ilaino) -1hidróxi-etil]-8-hidróxi-(1h)-quinolin-2-ona, útil como um agonista do adrenoceptor - Google Patents

processo para a preparação de sal de 5-[(r)-2-(5,6-dietil-indan-2-ilaino) -1hidróxi-etil]-8-hidróxi-(1h)-quinolin-2-ona, útil como um agonista do adrenoceptor

Info

Publication number
BRPI0407904A
BRPI0407904A BRPI0407904-3A BRPI0407904A BRPI0407904A BR PI0407904 A BRPI0407904 A BR PI0407904A BR PI0407904 A BRPI0407904 A BR PI0407904A BR PI0407904 A BRPI0407904 A BR PI0407904A
Authority
BR
Brazil
Prior art keywords
hydroxy
indan
diethyl
quinolin
ethyl
Prior art date
Application number
BRPI0407904-3A
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407904(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0407904A publication Critical patent/BRPI0407904A/pt
Publication of BRPI0407904B1 publication Critical patent/BRPI0407904B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE SAL DE 5-¢(R)-2-(5,6-DIETIL-INDAN-2-ILAMINO)-1-HIDRóXI-ETILI-8-HIDR óXI-(1H)QUINOLIN-2-ONA, úTIL COMO UM AGONISTA DO ADRENOCEPTOR". A presente invenção refere-se a um processo para a preparação de sal de 5-¢(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidróxi-etil!-8-hidróxi-(1H)-quinoli n-2-ona. O processo envolve a formação de um sal ácido de oxi-(1H)quinolin-2-ona 5-¢(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidróxi-etil!-8-substituída e coversão do sal ácido a um sal de 5-¢(R)-2-(5,6-dietil-indan-2-ilamino)-1hidróxi-etil!-8-hidróxi-(1H)-quinoli n-2-ona sem separação da base livre da 5¢(R)-2-(5,6-dietil-indan-2-ilamino)-1 -hidróxi-etil!-8-hidróxi-(1H)-quinolin-2-ona.
BRPI0407904A 2003-02-28 2004-02-27 processo para preparação de sal de 5-[(r)-2-(5,6-dietil-indan-2-ilamino) -1-hidróxi-etil]-8-hidróxi-(1h)-quinolin-2-ona, intermediários, bem como sal assim obtido BRPI0407904B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45094503P 2003-02-28 2003-02-28
PCT/EP2004/001981 WO2004076422A1 (en) 2003-02-28 2004-02-27 Process for preparing 5-‘(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist

Publications (2)

Publication Number Publication Date
BRPI0407904A true BRPI0407904A (pt) 2006-02-14
BRPI0407904B1 BRPI0407904B1 (pt) 2016-09-20

Family

ID=32927689

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407904A BRPI0407904B1 (pt) 2003-02-28 2004-02-27 processo para preparação de sal de 5-[(r)-2-(5,6-dietil-indan-2-ilamino) -1-hidróxi-etil]-8-hidróxi-(1h)-quinolin-2-ona, intermediários, bem como sal assim obtido

Country Status (29)

Country Link
US (1) US7534890B2 (pt)
EP (1) EP1599450B1 (pt)
JP (1) JP4802089B2 (pt)
KR (1) KR101076929B1 (pt)
CN (1) CN100363349C (pt)
AR (1) AR043406A1 (pt)
AT (1) ATE434609T1 (pt)
AU (1) AU2004215647B2 (pt)
BR (1) BRPI0407904B1 (pt)
CA (1) CA2517033C (pt)
CL (1) CL2004000381A1 (pt)
CY (1) CY1109442T1 (pt)
DE (1) DE602004021675D1 (pt)
DK (1) DK1599450T3 (pt)
EC (1) ECSP055977A (pt)
ES (1) ES2326974T3 (pt)
IL (1) IL170138A (pt)
MX (1) MXPA05009156A (pt)
MY (1) MY142491A (pt)
NO (1) NO331985B1 (pt)
NZ (1) NZ541727A (pt)
PE (1) PE20040956A1 (pt)
PL (1) PL213932B1 (pt)
PT (1) PT1599450E (pt)
RU (1) RU2332405C2 (pt)
SI (1) SI1599450T1 (pt)
TW (1) TWI324150B (pt)
WO (1) WO2004076422A1 (pt)
ZA (1) ZA200506060B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324151B (en) * 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
BRPI0409198A (pt) * 2003-04-04 2006-05-02 Novartis Ag derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
PT2044025E (pt) * 2006-06-30 2012-12-17 Novartis Ag Derivados de quinolinona e suas composições farmacêuticas
JP2010520188A (ja) 2007-02-28 2010-06-10 シプラ・リミテッド カルモテロールの異性体を調製する方法
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP3138837B1 (en) 2012-09-21 2021-11-24 Crystal Pharma, S.A.U. Indacaterol free base in solid form
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP2978745B1 (en) 2013-03-27 2017-03-15 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
PL3092217T3 (pl) 2014-01-09 2020-11-16 Davuluri, Ramamohan Rao Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli
WO2016027283A2 (en) 2014-08-22 2016-02-25 Reddy G Pratap A process for preparing indacaterol and salts thereof
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107074833B (zh) * 2015-07-21 2021-05-25 四川海思科制药有限公司 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109516974B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂的制备方法
WO2019135101A1 (en) 2018-01-02 2019-07-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN109988111A (zh) * 2019-05-06 2019-07-09 淮北师范大学 一种马来酸茚达特罗的杂质及其合成方法
CN110128339B (zh) * 2019-05-31 2022-03-08 苏州芝宇生物科技有限公司 一种茚达特罗及其盐衍生物的合成方法和合成用中间体
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
CZ296163B6 (cs) * 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7534890B2 (en) 2009-05-19
TW200505864A (en) 2005-02-16
CA2517033C (en) 2011-11-15
EP1599450B1 (en) 2009-06-24
AU2004215647A1 (en) 2004-09-10
CY1109442T1 (el) 2014-08-13
CN1753874A (zh) 2006-03-29
KR101076929B1 (ko) 2011-10-26
AU2004215647B2 (en) 2006-12-21
KR20050105258A (ko) 2005-11-03
ZA200506060B (en) 2006-07-26
ECSP055977A (es) 2006-01-16
ATE434609T1 (de) 2009-07-15
BRPI0407904B1 (pt) 2016-09-20
PL213932B1 (pl) 2013-05-31
PE20040956A1 (es) 2005-01-20
HK1086255A1 (en) 2006-09-15
PT1599450E (pt) 2009-08-31
JP2006519206A (ja) 2006-08-24
DK1599450T3 (da) 2009-10-05
EP1599450A1 (en) 2005-11-30
NZ541727A (en) 2008-07-31
SI1599450T1 (sl) 2009-12-31
CA2517033A1 (en) 2004-09-10
US20060252794A1 (en) 2006-11-09
WO2004076422A1 (en) 2004-09-10
RU2332405C2 (ru) 2008-08-27
MXPA05009156A (es) 2005-10-20
JP4802089B2 (ja) 2011-10-26
CN100363349C (zh) 2008-01-23
CL2004000381A1 (es) 2005-01-14
DE602004021675D1 (de) 2009-08-06
RU2005129547A (ru) 2007-04-10
IL170138A (en) 2011-09-27
NO20054452L (no) 2005-11-28
AR043406A1 (es) 2005-07-27
NO20054452D0 (no) 2005-09-26
ES2326974T3 (es) 2009-10-22
PL378358A1 (pl) 2006-03-20
NO331985B1 (no) 2012-05-21
TWI324150B (en) 2010-05-01
MY142491A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
BRPI0407904A (pt) processo para a preparação de sal de 5-[(r)-2-(5,6-dietil-indan-2-ilaino) -1hidróxi-etil]-8-hidróxi-(1h)-quinolin-2-ona, útil como um agonista do adrenoceptor
BRPI0918370B8 (pt) sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilaetoxi)hexila]amina}-1-hidroxietila)-8-hidroxiquinolin-2(1h)-ona como um agonista do receptor b2 adrenérgico e composição farmacêutica
WO2006121767A3 (en) 4-aminoquinoline compounds for treating virus-related conditions
NZ618004A (en) Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
BRPI0407903A (pt) protomicroemulsão, implemento de limpeza contendo a mesma, e método de uso do mesmo
IL261122A (en) Quinoline (theo) carboxamide derivatives kill microorganisms
EE200100167A (et) 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
EA200971096A1 (ru) Терапевтические композиции и их применение
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
CL2009002097A1 (es) Mezcla herbicida que contiene picolinafeno y por lo menos un compuesto herbicida seleccionado entre acidos quinolincarboxilicos, quinclorac o el quinmerac; agente herbicida que contiene la mezcla; procedimiento para preparar dicho agente herbicida. (divisional 523-04)
HK1217328A1 (zh) 製備抗腫瘤劑 6-(7-((1-氨基環丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其結晶
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
ATE500225T1 (de) Verfahren zur herstellung von montelukast und salzen davon
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
MY155657A (en) 5-(2-{ [6- (2,2-difluoro-2-phenylethoxy) hexyl] amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function
WO2008001188A3 (en) An improved process for the preparation of substantially pure aripiprazole
SG11201810334SA (en) Lubricating compositions
WO2005062723A3 (en) An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates
MX2009007868A (es) Proceso para la preparacion de monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2[[(1r)-2-(4-metoxifenil)-1-metiletil ]amino]-etil]-2(1h)-quinolinona.
MY186998A (en) Process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline
MX2013005954A (es) Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.
WO2007148191A3 (en) An improved process for the preparation of aripiprazole
Vaiana et al. Antiplasmodial activities of 4-aminoquinoline–statine compounds
DE60302054D1 (en) Wasserfreie kristalline formen i und ii der 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carbonsäure (gatifloxacin)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 215/26; A61P 11/00

Ipc: C07D 215/26 (2011.01), A61P 11/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/09/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI